Prescient Therapeutics

Prescient Therapeutics is a clinical-stage oncology company based in South Melbourne, Australia, focused on developing innovative therapies for various cancers. The company's lead drug candidates include PTX-200, which is undergoing multiple clinical trials targeting HER2-negative breast cancer, relapsed and refractory acute myeloid leukemia, and recurrent platinum-resistant ovarian cancer, and PTX-100, a RhoA inhibitor aimed at treating hematological and solid tumors with specific mutations. Additionally, Prescient is developing OmniCAR, a universal immune receptor platform designed to enhance T-cell activity and enable multi-antigen targeting. The company has also established a collaboration with Carina Biotech to advance cell therapy initiatives. Originally incorporated in 1986 and previously known as Virax Holdings Limited, Prescient Therapeutics rebranded in December 2014 to reflect its focus on oncology.